There is an urgent need for new therapies to treat non-small cell lung cancer (NSCLC)
because current chemotherapy regimens are of limited effectiveness. The role of vascular …

Angiogenesis, the growth of new vessels from preexisting vessels, is a fundamental step in
tumor growth and progression. Vascular endothelial growth factor (VEGF) is a key …

Abstract Learning Objectives After completing this course, the reader will be able to: Identify
the role of angiogenesis in non-small cell lung cancer (NSCLC). Explain the role of …

Lung cancer continues to be the leading cause of cancer death in Western countries. The
median survival time for advanced non-small cell lung cancer (NSCLC) remains poor and …

Background Bevacizumab, a monoclonal antibody against vascular endothelial growth
factor, has been shown to benefit patients with a variety of cancers. Methods Between July …

Bevacizumab, is a humanized monoclonal antibody to vasculo-endothelial-growth-factor,
with anticancer activity in non-small-cell-lung cancer (NSCLC) patients. Our previous results …

New blood vessel formation, known as angiogenesis is a fundamental event in the process
of tumor growth and metastatic dissemination. Due to its central role in tumor angiogenesis …

Study Design The ECOG 4599 trial enrolled 878 previously untreated patients with
advanced nonsquamous cell NSCLC with histologically or cytologically confirmed stage IIIB …

The long-term prognosis for patients with advanced non–small cell lung cancer (NSCLC)
remains poor despite the availability of several cytotoxic chemotherapy regimens. The use of …

Non-small-cell lung cancer (NSCLC) represents about 85% of all lung cancers, and more
than half of NSCLCs are diagnosed at an advanced stage. Chemotherapy has reached a …